Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Net Income (2016 - 2025)

Historic Net Income for Altimmune (ALT) over the last 17 years, with Q3 2025 value amounting to -$19.0 million.

  • Altimmune's Net Income rose 1676.95% to -$19.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$84.0 million, marking a year-over-year increase of 1882.44%. This contributed to the annual value of -$95.1 million for FY2024, which is 752.99% down from last year.
  • As of Q3 2025, Altimmune's Net Income stood at -$19.0 million, which was up 1676.95% from -$22.1 million recorded in Q2 2025.
  • Over the past 5 years, Altimmune's Net Income peaked at -$14.9 million during Q1 2021, and registered a low of -$33.5 million during Q3 2021.
  • In the last 5 years, Altimmune's Net Income had a median value of -$22.1 million in 2025 and averaged -$22.4 million.
  • As far as peak fluctuations go, Altimmune's Net Income plummeted by 28253.86% in 2021, and later surged by 2983.29% in 2022.
  • Altimmune's Net Income (Quarter) stood at -$23.9 million in 2021, then grew by 9.33% to -$21.7 million in 2022, then tumbled by 46.08% to -$31.6 million in 2023, then increased by 26.37% to -$23.3 million in 2024, then rose by 18.39% to -$19.0 million in 2025.
  • Its Net Income stands at -$19.0 million for Q3 2025, versus -$22.1 million for Q2 2025 and -$19.6 million for Q1 2025.